Barclays analyst Gena Wang raised the firm’s price target on Ionis Pharmaceuticals to $51 from $45 and keeps an Equal Weight rating on the shares post the Q2 report. Ionis reported a beat quarter, largely driven by higher collaborative revenue, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis reports second quarter 2024 financial results
- IONS Upcoming Earnings Report: What to Expect?
- Tesla downgraded, Spotify upgraded: Wall Street’s top analyst calls
- Ionis Pharmaceuticals upgraded to Outperform from Market Perform at Leerink
- Ionis Pharmaceuticals price target raised to $68 from $67 at BofA